SCHEMBL15034239

SCHEMBL15034239

CC1(C)CN(C(=O)c2cccc(Cl)c2)CCN1C(=O)c1ncn(-c2cccc(F)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
HTT P42858 1/20 0.49
MGLL Q99685 3/20 0.45
GRM5 P41594 2/20 0.42
ALDH1A1 P00352 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 3/20 0.41
CYP3A4 P08684 3/20 0.41
USP2 O75604 2/20 0.41
HIF1A Q16665 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
SLC6A7 Q99884 1/20 0.40
HSD17B10 Q99714 2/20 0.40
ALOX12 P18054 1/20 0.40
TSHR P16473 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15019972 0.95 SLC6A7 (0.43) SMN1; SMN2HTTMGLLGRM5ALDH1A1
SCHEMBL15020006 0.91 ALDH1A1 (0.44) SMN1; SMN2HTTGRM5ALDH1A1L3MBTL1
SCHEMBL15034215 0.90 HPGD (0.43) SMN1; SMN2HTTMGLLGRM5ALDH1A1
SCHEMBL15034131 0.89 CYP3A4 (0.48) SMN1; SMN2HTTMGLLALDH1A1HPGD
SCHEMBL15034233 0.89 GRM5 (0.43) SMN1; SMN2HTTMGLLGRM5ALDH1A1
SCHEMBL15034089 0.89 MGLL (0.46) SMN1; SMN2HTTMGLLALDH1A1L3MBTL1
SCHEMBL15034036 0.89 ALDH1A1 (0.44) SMN1; SMN2HTTMGLLGRM5ALDH1A1
SCHEMBL15034035 0.88 MGLL (0.46) SMN1; SMN2HTTMGLLGRM5HPGD
SCHEMBL15034054 0.88 SLC6A7 (0.43) SMN1; SMN2HTTMGLLALDH1A1HPGD
SCHEMBL15034067 0.87 GRM5 (0.47) MGLLGRM5ALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 SMN1; SMN2 2592/4885HTT 724/4885MGLL 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.